Valuation: Autolus Therapeutics plc

Market Cap 482M 432M 402M 365M 688M 46.13B 692M 4.84B 1.89B 23.76B 1.81B 1.77B 76.37B P/E 2026 *
-2.25x
P/E 2027 * -2.65x
Enterprise Value 326M 292M 272M 247M 465M 31.19B 468M 3.27B 1.28B 16.06B 1.22B 1.2B 51.63B EV / Sales 2026 *
2.17x
EV / Sales 2027 * 2.1x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day-3.87%
1 week-4.92%
Current month-10.31%
1 month-7.45%
3 months+8.07%
6 months+16.78%
Current year-12.56%
1 week 1.72
Extreme 1.72
1.82
1 month 1.72
Extreme 1.72
2.08
Current year 1.18
Extreme 1.175
2.58
1 year 1.18
Extreme 1.175
2.58
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 31/08/2014
Chief Executive Officer 61 29/02/2016
Director of Finance/CFO 56 06/08/2023
Director TitleAgeSince
Chairman 61 30/09/2014
Director/Board Member 78 31/07/2014
Director/Board Member 71 28/02/2018
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/26 Sell

Executive/Senior Manager

-6,713 0.0025%
29/06/26 Free

Director

79,167 0.0477%
18/03/26 Other

Chief Executive Officer

6,917,877 4.1641%
Change 5-day change 1-year change 3-year change Capi.($)
-3.87%-4.92%+4.82%-24.68% 482M
+0.28%+3.46%+41.89%+93.71% 1,051B
+0.88%+4.27%+38.28%+68.70% 630B
+1.68%+5.78%+21.96%+89.56% 489B
-0.10%+4.24%+69.15%+40.41% 359B
+0.61%+3.18%+24.05%+42.46% 344B
+0.72%+2.99%+14.29%+34.71% 272B
+0.23%+2.23%-5.91%+8.15% 246B
+0.65%+3.62%+43.93%+46.50% 224B
-0.49%+4.01%+28.38%+95.97% 187B
Average +0.00%+2.74%+28.08%+49.55% 380.42B
Weighted average by Cap. +0.42%+2.93%+34.07%+66.91%

Financials

2026 *2027 *
Net sales 150M 134M 125M 113M 214M 14.34B 215M 1.5B 589M 7.39B 563M 550M 23.74B 192M 172M 161M 146M 275M 18.43B 277M 1.93B 756M 9.49B 723M 707M 30.5B
Net income -219M -196M -183M -166M -312M -20.96B -315M -2.2B -860M -10.79B -822M -804M -34.69B -185M -166M -155M -140M -265M -17.75B -267M -1.86B -729M -9.14B -696M -681M -29.39B
Net Debt -156M -140M -130M -118M -223M -14.94B -224M -1.57B -613M -7.69B -586M -573M -24.73B -77.38M -69.33M -64.54M -58.58M -110M -7.41B -111M -777M -304M -3.82B -291M -284M -12.27B
Projected Income Statement - Annual - Autolus Therapeutics plc
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
12/10/26 US$1.740 -3.87% 1,052,603
09/10/26 US$1.810 +2.26% 1,476,345
08/10/26 US$1.770 -2.21% 1,602,301
07/10/26 US$1.810 +1.12% 1,551,347
06/10/26 US$1.790 -2.19% 1,682,568
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Autolus Therapeutics plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.740USD
Average target price
8.725USD
Spread / Average Target
+401.44%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Autolus Therapeutics plc
  1. Stock Market
  2. Stocks
  3. AUTL Stock